SCHEMBL1025959

SCHEMBL1025959

O=C(Nc1ccccc1)[C@H]1CCC[C@@H]1N1C(=O)C=CC1=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.54
GAA P10253 2/20 0.54
RAB9A P51151 3/20 0.50
LMNA P02545 1/20 0.50
HPGD P15428 1/20 0.50
POLB P06746 3/20 0.49
L3MBTL1 Q9Y468 2/20 0.48
TDP1 Q9NUW8 2/20 0.48
FNTA P49354 1/20 0.47
FNTB P49356 1/20 0.47
MEN1 O00255 1/20 0.45
GFER P55789 1/20 0.45
KMT2A Q03164 1/20 0.45
KDM4E B2RXH2 2/20 0.45
SMN1; SMN2 Q16637 3/20 0.44
HTT P42858 2/20 0.44
ALDH1A1 P00352 2/20 0.44
CYP1A2 P05177 1/20 0.44
GRK2 P25098 1/20 0.44
CASP6 P55212 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1027699 0.79 ALDH1A1 (0.58) LMNAHPGDSMN1; SMN2HTTALDH1A1
SCHEMBL10337750 0.79 MAPT (0.78) MAPTGAARAB9ALMNAHPGD
SCHEMBL105931 0.79 MAPT (0.78) MAPTGAARAB9ALMNAHPGD
SCHEMBL1028238 0.79 MCL1 (0.44) MAPTHPGDTDP1MEN1KMT2A
SCHEMBL1028652 0.78 GRM4 (0.41) GAAKDM4ESMN1; SMN2HTTALDH1A1
SCHEMBL1027579 0.78 LMNA (0.53) RAB9ALMNAPOLBL3MBTL1SMN1; SMN2
SCHEMBL1025056 0.77 TAAR1 (0.64) GAAPOLBL3MBTL1MEN1KMT2A
SCHEMBL1029850 0.76 KCNQ3 (0.39) MAPTGAALMNAHPGDPOLB
SCHEMBL1028000 0.75 ALDH1A1 (0.44) HPGDPOLBL3MBTL1MEN1KMT2A
SCHEMBL1026434 0.75 SLC6A3 (0.43) GAARAB9APOLBL3MBTL1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1479669-B1 Optically active maleimide derivatives and polymaleimides for use as chiral adsorbent in chromatography TOSOH CORP (JP) 2011-01-19 EP disclosed
US-7645889-B2 Optically active polymaleimide derivatives and process for their production TOSOH CORPORATION (JP) 2010-01-12 US disclosed
US-20080230482-A1 Optically active polymaleimide derivatives and process for their production TOSOH CORPORATION (JP) 2008-09-25 US disclosed
US-7381742-B2 Optically active polymaleimide derivatives and process for their production TOSOH CORPORATION (JP) 2008-06-03 US disclosed
US-20070131616-A1 Optically active maleimide derivatives, optically active polymaleimide derivatives, process for their production, separating media comprising the optically active polymaleimide derivatives and method of separating optically active compounds using them TOSOH CORPORATION (JP) 2007-06-14 US disclosed
US-7186750-B2 Optically active maleimide derivatives, optically active polymaleimide derivatives, process for their production, separating media comprising the optically active polymaleimide derivatives and method of separating optically active compounds using them TOSOH CORPORATION (JP) 2007-03-06 US disclosed
US-20040235937-A1 Optically active maleimide derivatives, optically active polymaleimide derivatives, process for their production, separating media comprising the optically active polymaleimide derivatives and method of separating optically active compounds using them TOSOH CORPORATION (JP) 2004-11-25 US disclosed
EP-1479669-A1 Optically active maleimide derivatives and polymaleimides for use as chiral adsorbent in chromatography Tosoh Corporation (JP) 2004-11-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080230482-A1 Optically active polymaleimide derivatives and process for their production CYBA, COASY, MEP1B MAPT 1183/4885GAA 2733/4885RAB9A 2666/4885
US-20040235937-A1 Optically active maleimide derivatives, optically active polymaleimide derivatives, process for their production, separating media comprising the optically active polymaleimide derivatives and method of separating optically active compounds using them MACF1, MEP1B, CYBA MAPT 1166/4885GAA 3324/4885RAB9A 2132/4885
US-20070131616-A1 Optically active maleimide derivatives, optically active polymaleimide derivatives, process for their production, separating media comprising the optically active polymaleimide derivatives and method of separating optically active compounds using them MACF1, MEP1B, ACMSD MAPT 1189/4885GAA 3292/4885RAB9A 2141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.